ReviewFrontiers in cell and developmental biology2025
Targeting tumor angiogenesis and metabolism: a new perspective in pediatric thoracic tumor therapy.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modulation of the ACLY-AMPK axis by bempedoic acid suppresses NF-κB-driven inflammation, VEGF-Notch angiogenic crosstalk, and cell-cycle progression in Solid Ehrlich Carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Breaking the barrier: a guidelines-based review of antiangiogenesis drug resistance in pediatric cancer therapy.Clinical and experimental pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric thoracic solid tumors encompass mediastinal tumors, chest wall tumors, and lung tumors. The pathogenesis is complex, and the clinical presentation is diverse, presenting numerous challenges in diagnosis and treatment, which severely threaten the life and health of the affected children. Angiogenesis provides nutritional and oxygen support for tumor growth and metastasis, while metabolic reprogramming meets the unique energy and material demands of tumor. Both processes play key roles in pediatric thoracic tumor development. Therefore, targeting tumor vasculature could be an important therapeutic strategy, and exploring the molecular mechanisms of metabolic reprogramming may provide a theoretical foundation for targeted treatment. This review summarizes relevant experimental research on angiogenesis and metabolic reprogramming in pediatric thoracic tumors, analyzes the limitations of current research, and proposes solutions and recommendations. Through this review, we aim to provide comprehensive information about pediatric thoracic solid tumors for clinicians and researchers, promoting personalized treatment, and ultimately improve survival rates and quality of life for affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.